Welcome

Celebrating Over 75 Years Of Service

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Dedicated to enhancing knowledge and skill in the care of the allergic patient."

ADVOCACY UPDATES

What you need to comply with the pending USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations

3 key compliance criteria While the implementation date of the new USP General Chapter <797>…

read more

2019 AAOA Advanced Course in Allergy & immunology Optional USP 797 Compliance Workshop

Cost: $125 for AAOA members and $300 for non-members* in addition to AAOA Advanced Course registration…

read more

NEWS! USP General Chapter <797> Implementation Postponed

The United States Pharmacopeia announced that, due to appeals underway, the previously announced implementation date…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

12/01/19: Research Grant Cycle
Learn more

02/15/20: Crowdsourcing for 2020 Scottsdale
Learn more

02/15/20: Call for Proposals
Learn more

04/01/20: Fellow Exam Application Deadline
Learn more

06/01/20: Research Grant Cycle
Learn more

06/26/20: Membership Application Deadline to be eligible for AAOA Member rate for the 2020 Basic Course Learn more

09/11/20: Membership Application Deadline to be voted in at the 2020 Annual Meeting and to be eligible for AAOA Member Rate (FREE) for the 2020 Annual Meeting Learn more

EDUCATION

Here is What You Missed...

2019 New Orleans was an outstanding success?  With over 500 participants, our AAOA members left New Orleans re-energized, re-freshed, and re-engaged.  The program offered something for everyone — from cutting edge clinical content to every day how to’s for practice management efficiencies. Read More

AAOA in the Lone Star

Join us in the Lone Star State for the 2019 AAOA Advanced Course in Allergy and Immunology. This course builds on the basic clinical care of allergic patient concepts and techniques presented at the AAOA’s Basic Course in Allergy & Immunology. Read More

IFAR

IFAR Impact Factor: 2.454

aaoaf-ifar

Now Available

Changes in Managing Practices

Mission

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2019 Advanced Course in Allergy & Immunology
December 12-14 | Austin, TX
Learn More and Register

2020 Basic Course in Allergy & Immunology
July 9-11 | Orlando, FL
Save the Date

2020 AAOA Annual Meeting
October 23-25| Scottsdale, AZ
Save the Date

AAOA Clinical Insights
Learn More and Register

PATIENT CORNER

Off to College: Tips for Managing Allergies

Heading to college is an exciting time. What are the best ways for students to avoid exacerbation of their symptoms as they enter the hallowed halls of higher learning?

Read More

College Allergy Symptoms Treatment Back to Shcool

News and Updates

Should I Go to Austin?

We get it.  You’ve been to the Advanced Course on Allergy & Immunology, so you…

read more

CEO September 2019 Update

by Jami Lucas, AAOA CEO/Executive Director Over 500 AAOA members were engaged, learning, and networking…

read more

Here is What You Missed…

2019 New Orleans was an outstanding success?  With over 500 participants, our AAOA members left…

read more

Menu
AAOA Logo

About Us

AAOA SCOPE OF KNOWLEDGE: ALLERGY AND ASTHMA

You can also download The Scope of Knowledge PDF.

I Epidemiology

A. Prevalence

  • i Regional
  • ii Change Over Time

B. Populations at risk

  • i Genetic associations
  • ii Environmental associations

C. Socioeconomic impact of disease

  • i Direct cost
  • ii Indirect costs
  • iii Quality of life

II Science of the Sites of Allergic Inflammation

A. Anatomy, Histology, physiology, pathophysiology of:

  • i Nose and paranasal sinuses
  • ii Pharynx
  • iii Ear/Eustachian Tubes
  • iv Larynx/Trachea
  • v Lungs
  • vi Eye
  • vii Skin
  • viii Gastrointestinal tract

B. Basic physiology, pathophysiology, and principles of:

  • i Mucociliary function
  • ii Smell and taste
  • iii Auditory/vestibular function
  • iv Voice
  • v Respiratory function
  • vi Deglutition
  • vii Ocular protection mechanisms
    • 1 Naso–lacrimal function
    • 2 Conjunctival function
  • viii GI function

III Basic Science

A. Basic components, concepts and applications pertinent to Allergy:

  • i Immunology
    • 1. Function
      • a. General aspects
        • i Recognition
        • ii Surveillance
        • iii Amplification
        • iv Memory
      • b. Triggers of the immune response
        • i Allergens, haptens, epitopes, parasites, macromolecules
      • c. Categories of response
        • i Innate
        • ii Adaptive
    • 2. Components
      • a. Inflammatory cells
        • i Macrophages (APC)
        • ii Lymphoid
          • 1 T–cells
          • 2 B–Cells
          • 3 Null cells
        • iii Granulocytes
          • 1 Mast Cells/basophils
          • 2 Eosinophils
          • 3 Neutrophils
          • 4 Platelets
      • b. Immunoglobulins
        • i G
        • ii A
        • iii M
        • iv D
        • v E
      • c. Inflammatory mediators
        • i Cytokines
        • ii Chemokines
        • iii Vasoactive amines
        • iv Leukotrienes
        • v Prostaglandins
        • vi Complement
  • ii Endocrinology
  • iii Neurology
  • iv Molecular cell biology
  • v Genetics

B. Physiology and pathophysiology

  • i Immunology
    • 1. Cellular communication
      • a. Direct contact
        • i Antigen specific
      • b. Cytokine/Chemokine mediated
        • i Non-antigen specific
    • 2. Inflammatory pathways
      • a. Cellular
        • i Microphage
        • ii Granulocyte
          • 1 Mast Cell/Basophils
          • 2 Eosinophil
      • b Non-cellular
        • i Complement
        • ii Arachadonic Acid cascade
        • iii Other
    • 3. Immune sensitization
      • a Memory
    • 4. Hypersensitivity (Gel and Coombs)
      • a I
      • b II
      • c III
      • d IV
      • e V
      • f VI
  • ii Allergic response (Type I)
    • 1 Allergy sensitization
      • a Antigen processing
      • b T-cell
      • c B-cell
      • d IgE
      • e Mast cell
    • 2 Subsequent exposure—trigger
      • a Mast Cell
        • i Antigen crosslinking
        • ii Degranulation
          • 1 Preformed mediators
          • 2 Newly synthesized mediators
          • 3 Cytokines
      • b Early phase response
      • c Late phase response
        • i Cellular Components
      • d Priming
  • iii Microbiology
    • 1 Parasitology
    • 2 Bacteriology
    • 3 Virology
    • 4 Mycology
  • iv Endocrinology
  • v Neurology
  • vi Molecular cell biology
  • vii Genetics
  • viii Nutrition

IV Diseases, Disorders, and Conditions

A. Differential diagnosis of inflammatory disease:

  • i Nose/paranasal sinus
  • ii Otologic
  • iii Laryngopharyngeal
  • iv Tracheobronchial
  • v Thoracic/Pulmonary
  • vi Gastrointestinal
  • vii Ocular
  • viii Cutaneous

B. Immunologic disorders

  • i. Allergic diseases
    • 1. Allergic Rhinitis
    • 2. Allergic conjunctivitis
    • 3. Otologic disease
      • a. Otitis media
      • b. Meniere’s
      • c. Otitis externa
      • d. Eustachian tube dysfunction
    • 4. Asthma
    • 5 Dermatitis
      • a. Eczema
      • b. Contact
      • c. Urticaria/Angioedema
    • 6. Allergic laryngitis
    • 7. Gastrointestinal
      • a. Eosinophilic esophagitis
  • ii Co-morbid conditions impacted by allergy
    • 1. Rhinosinusitiss
    • 2. Otitis media
    • 3. Eustachian tube dysfunction
    • 4. Disordered sleep
    • 5. Laryngeal/pharyngeal/esophageal disorders
      • a. GERD
    • 6. Asthma
  • iii Immunodeficiency
  • iv Autoimmune diseases

V Diagnostics and Assessment Procedures

A. History

  • i Symptoms
    • 1. Onset, duration, severity
    • 2. Triggers
    • 3. Exacerbating or ameliorating factors
  • ii Exposures
    • 1. Temporal relationships
      • a. Intermittent
      • b. Persistent
    • 2. Identifiable antigen
      • a. Aeroantigens (Inhalants)
      • b. Ingestants
      • c. Contactants
      • d. Injectants
  • iii Co-morbid conditions
    • 1. Rhinosinusitiss
    • 2. Otitis media
    • 3. Eustachian tube dysfunction
    • 4. Disordered sleep
    • 5. Laryngeal/pharyngeal/esophageal disorders
      • a. GERD
    • 6. Asthma
    • 7. Ocular
  • iv Family/childhood history

B. Physical examination

  • i Face
  • ii Ears
  • iii Nose/Paranasal sinues
  • iv Oro/Nasopharynx
  • v Laryngotracheal
  • vi Pulmonary
  • vii Skin

C. Adjunctive testing: Indications, limitations, and normal and pathologic findings:

  • i Ears
    • 1. Audiovestibular testing
  • ii Nose
    • 1. Acoustic rhinometry/rhinomanometry
    • 2. Nasal cytology/biopsy
    • 3. Nasal/paranasal sinus culture
    • 4. Nasal endoscopy
    • 5. Olfactory testing
    • 6. Radiologic testing
  • iii Larynx
    • 1. Laryngoscopy
  • iv Pulmonary
    • 1. Pulmonary function testing
    • 2. Radiologic testing
  • v Sleep
    • 1. Polysomnography

D. Allergy testing:

    • i Antigen selection
      • 1. Antigen characteristics
        • a. Aeroallergen physical characteristics
        • b. Biologic activity/potency
        • c. Antigen cross reactivity
        • d. Antigen extraction/standardization
      • 2. Aeroallergen distribution
        • a. Principles of distribution
        • b. Local and Regional differences
      • ii Aeroallergen tests
        • 1. Expanded specific allergen testing
          • a. In vivo
            • i Principles of in vivo testing
              • 1. Pathophysiology of the skin whealing response
                • a. Immediate response
                • b. Delayed response
              • 2. Factors that affect the skin whealing response
            • ii Specific methodologies
              • 1. Percutaneous (Prick) testing
                • a. Single percutaneous (prick) testing
                • b. Multi percutaneous (prick) testing
              • 2. Intradermal testing
                • a. Single intradermal testing
                • b. Intradermal dilutional testing
              • 3. Blended techniques of in vivo testing
              • 4. Scratch testing (mentioned only for historical purposes)
              • 5. Provocation
          • b. In vitro
            • i Principles of in vitro testing
            • ii Methodologies
    • 2. Principles of the allergen screen
      • iii Ingestants (Food Allergy)
        • 1. History
          • a. Food diary
          • b. Anaphylaxis
        • 2. Testing
      • iv Injectants
      • v Contactants
        • 1. Contact tests (patch)

E. Immunologic Evaluation (including rheumatologic)

      • i Humoral
      • ii Cellular

VI Allergy Treatment

A. Environmental control
B. Pharmacotherapy/pharmacology

      • i Antihistamines
      • ii Decongestants
      • iii Mast cell stabilizers
      • iv Mucolytics
      • v Leukotriene modifiers
      • vi Corticosteroids

C. Dietary control

D. Immunotherapy

    • i. Desensitization
      • 1. Route of delivery
        • a. Subcutaneous
        • b. Mucosal (e.g., sublingual)
      • 2. Mechanism of action/li>
      • 3. Indications/contraindications
      • 4. Antigen dosing
        • a. Starting dose
        • b. Escalation
        • c. Maintenance
        • d Withdrawal
      • 5. Mixing of treatment vial
      • 6. Duration of therapy
      • 7. Outcomes of immunotherapy
    • ii Monoclonal antibody

VII Allergy Emergencies


A. Epidemiology

  • i Risk factors
  • ii Recognition
  • iii Differential diagnosis

B. Management

  • i High-risk population recognition
  • ii Preparation
  • iii Prevention
  • iii Intervention
scope

Register For Live Classes

2017 Advanced Course in Allergy & Immunology
December 6-9 | Vail, CO.
Learn more and Register

2018 Interactive Allergy & Rhinology Course
February 22-24 | Dallas, TX
Save the Date

2018 Basic Course in Allergy & Immunology
July 5-7 | Hollywood, FL
Save the Date

2018 AAOA Annual Meeting
September 14-16 | Philadelphia, PA
Save the Date

Clinical Insights With Wiley
Start Learning Now

Spotlight/News

Recent Blog Articles

CEO September 2019 Update

by Jami Lucas, AAOA CEO/Executive Director Over 500 AAOA…

read more

Here is What You Missed…

2019 New Orleans was an outstanding success?  With over…

read more

A Message from AAOA President, Alpen Patel, MD

Alpen Patel, MD, FAAOA is currently serving as 2019-2020…

read more

* Adapted from Marple, BF, et al. “American Academy of Otolaryngic Allergy CME Report: Allergy, Scope of Knowledge.” Otolaryngology—Head and Neck Surgery, 136(1): 8-10, 2007 Jan